sameAs
HIV-1 envelope-receptor interactions required for macrophage infection and implications for current HIV-1 cure strategiesImpact of antiretroviral therapy (ART) timing on chronic immune activation/inflammation and end-organ damageOngoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory AgentsThe end of AIDS: HIV infection as a chronic diseaseDecreased NK Cell FcRgamma in HIV-1 infected individuals receiving combination antiretroviral therapy: a cross sectional studyAn in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patientsActivation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapyIs Australia prepared for the next pandemic?Modeling of Experimental Data Supports HIV Reactivation from Latency after Treatment Interruption on Average Once Every 5-8 Days.Reduced hepatitis B virus (HBV)-specific CD4+ T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy.Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfectionShort communication: CD4 T cell declines occurring during suppressive antiretroviral therapy reflect continued production of Casp8p41.Relationship of Human Immunodeficiency Virus Viral Load in Cerebrospinal Fluid and Plasma in Patients Co-infected With Cryptococcal Meningitis.No increase in hepatitis B virus (HBV)-specific CD8+ T cells in patients with HIV-1-HBV coinfections following HBV-active highly active antiretroviral therapy.Hepatitis B and Delta virus are prevalent but often subclinical co-infections among HIV infected patients in Guinea-Bissau, West Africa: a cross-sectional studyHIV persistence: chemokines and their signalling pathways.Normal T-cell turnover in sooty mangabeys harboring active simian immunodeficiency virus infection.Use of real-time PCR and molecular beacons to detect virus replication in human immunodeficiency virus type 1-infected individuals on prolonged effective antiretroviral therapy.Compartmentalization of innate immune responses in the central nervous system during cryptococcal meningitis/HIV coinfectionEntinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells.Coinfection of hepatic cell lines with human immunodeficiency virus and hepatitis B virus leads to an increase in intracellular hepatitis B surface antigen.Endosomal NOX2 oxidase exacerbates virus pathogenicity and is a target for antiviral therapy.Differential expression of CD163 on monocyte subsets in healthy and HIV-1 infected individuals.Clinical predictors of immune reconstitution following combination antiretroviral therapy in patients from the Australian HIV Observational Database.Splenectomy associated changes in IgM memory B cells in an adult spleen registry cohort.Pathogenicity and immunogenicity of attenuated, nef-deleted HIV-1 strains in vivo.Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individualsFactors associated with elevated ALT in an international HIV/HBV co-infected cohort on long-term HAARTHBV mutations in untreated HIV-HBV co-infection using genomic length sequencing.Establishment of HIV-1 latency in resting CD4+ T cells depends on chemokine-induced changes in the actin cytoskeleton.Circulating heat shock protein 60 levels are elevated in HIV patients and are reduced by anti-retroviral therapyNo difference in the rate of change in telomere length or telomerase activity in HIV-infected patients after three years of darunavir/ritonavir with and without nucleoside analogues in the MONET trialFinding a cure for HIV: will it ever be achievable?Towards an HIV cure: a global scientific strategyHIV infection: epidemiology, pathogenesis, treatment, and prevention.Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfected individuals.Pharmacy adherence measures to assess adherence to antiretroviral therapy: review of the literature and implications for treatment monitoring.Plasma levels of soluble CD14 independently predict mortality in HIV infection.Hepatitis B treatment: rational combination chemotherapy based on viral kinetic and animal model studies.Persistent immune activation in chronic HIV infection: do any interventions work?
P50
Q26825087-B4288480-F497-4A10-90B3-CD66FC5356C4Q27014077-4692F76D-4830-4D25-99EB-C52AC60674F7Q28079455-A4BBF836-494C-4ACB-8F75-A0728A567857Q28300749-DFB337DC-7A17-4142-87DD-B284EADF9733Q28473151-ACC7085C-E17B-4438-8A85-7A89C8EAB292Q28538015-8720ECE6-190E-4646-A329-A7EE3A672139Q28544949-1F55E4BB-D98A-4A22-A0B6-054B29DFCDFBQ30401023-8120125D-CB6B-40FE-9EE0-6B973B34B2D0Q31123548-B1F98FB3-F972-4214-B9B5-6DC1A4C663BBQ33211869-1EC382D8-6C57-4BF1-AD81-7CA4A905343FQ33449162-9C5E1DE1-247E-46CD-AF16-B560A142F25FQ33566570-E8D16A1E-E03D-4202-89C9-8475E2B71BA2Q33609454-0754486B-BB11-4C77-B20E-20924C2F2F45Q33676594-17A2CF02-8C12-40C9-820D-D1676CC0390EQ33734612-20100A67-CB99-421C-A6DC-B72198A83220Q33774665-B78A0E7C-AD35-4DB2-A6FA-04EFF71A9067Q33793153-8AB05F58-BC5D-43B3-A119-8A17234D5BF3Q33816010-433A2568-321F-4020-9394-F2A15344A32EQ33831703-588F333D-FCB7-4B6E-93F2-46D14D8EA4F4Q33838633-344B7D3D-246C-4E07-801C-8E28598F6287Q33877464-15C7630D-E4D5-494D-97C9-546DE93DF7F4Q33899570-5F35C471-6E04-493C-8EE2-0139B23F8065Q33916381-3CF5545E-2851-433F-A669-57B645BA041EQ33933071-5942D23E-702F-4D07-8B73-FCF78D6CDE78Q33988782-65D23667-C179-4EC0-BAB0-6F70DB460973Q34007084-E3709668-C5F4-4203-88BB-AC4F2075396AQ34052838-383DE26D-F0C7-4E7B-9383-E9AEA40A4DFCQ34070485-230E6710-BDAD-4CF4-ADA6-07640803F668Q34112620-2F3972F0-457A-4600-AC71-D92D7F83CBD7Q34165677-901C3FB4-9ED1-44AC-AA79-97BDD23EB310Q34428634-BDF3D697-FD8E-4438-B59F-16B3979CD569Q34450075-9A971D5A-7DA7-45FD-9BC7-5C9FEAD699E4Q34567084-A08717E0-752A-46CF-BEF0-B4FFFECA0CB1Q34640562-233D0FEE-1E2F-4E13-8972-D1FAE1A7A611Q34662270-02FE5A2B-A94F-4A02-82CE-2E4C57D7CF5CQ34674838-D86518C2-E13A-496C-B742-6A6B235193D4Q34699180-09C02C1B-E226-4AD4-8C73-672955C10C71Q34764002-58A3FE24-605D-457B-B03D-84CEF44CC507Q34807240-0FD293D8-994A-4569-9CFA-0872169F33BDQ34851102-1D513D47-6A06-4A12-94F5-6A39C373EDE5
P50
description
Australian infectious disease physician and researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Sharon Lewin
@ast
Sharon Lewin
@es
Sharon R Lewin
@nl
Sharon R Lewin
@sl
Sharon R. Lewin
@en
type
label
Sharon Lewin
@ast
Sharon Lewin
@es
Sharon R Lewin
@nl
Sharon R Lewin
@sl
Sharon R. Lewin
@en
altLabel
Sharon Lewin
@en
Sharon Lewin
@nl
Sharon Ruth Lewin
@en
prefLabel
Sharon Lewin
@ast
Sharon Lewin
@es
Sharon R Lewin
@nl
Sharon R Lewin
@sl
Sharon R. Lewin
@en
P108
P106
P108
P1153
15737239300
P21
P31
P373
Sharon Lewin
P496
0000-0002-0330-8241